Search - tctmd.com

Displaying 161 - 180 of 310

Sort: Relevancy | Date

Presentation TCT 2015

Which Valve, Which Size, and Why, Part 2? Self Expanding

Presenter: Susheel Kodali, Jean-Claude Laborde

October 14, 2015

Presentation TCT 2015

Which Valve, Which Size, and Why, Part 1? Balloon Expandable

Presenter: Susheel Kodali, Jean-Claude Laborde

October 14, 2015

Presentation Aortovascular 2015

Transfemoral TAVR: Current indications and results

Presenter: Susheel K. Kodali

September 19, 2015

News Daily News

已有或新发房颤均会使TAVR疗效变差

Yael L. Maxwell

August 30, 2015

News Daily News

La FA, Preexistente o de Nueva Aparición, se asoció a Peores Resultados en la TAVR

Yael L. Maxwell

August 30, 2015

News Daily News

A-fib, Whether Preexisting or New-Onset, Tied to Poor Outcomes in TAVR

Yael L. Maxwell

August 30, 2015

Presentation TVT 2015

An Interventionalists View: Flying Solo or With a Copilot?

Presenter: Susheel K. Kodali, David A. Wood, Ganesh Manoharan

June 06, 2015

Presentation TVT 2015

A Surgeons View: Will I Be in the Room in the Future?

Presenter: Susheel K. Kodali, David A. Wood, Michael J. Reardon

June 06, 2015

Presentation TVT 2015

The Era of Tailored Care: Implementing Risk Stratification and Individualized Device Selection

Presenter: Susheel K. Kodali, David A. Wood, Nicolas M. Van Mieghem

June 06, 2015

Presentation TVT 2015

New Indications Coming: The Role of the Heart Team in the Assessment of Intermediate- and Low-Risk Patients

Presenter: Susheel K. Kodali, David A. Wood

June 06, 2015

Presentation TVT 2015

Looking Back to Move Forward: Learning From Past Blunders to Strengthen the Heart Team

Presenter: Susheel K. Kodali, David A. Wood, Ian T. Meredith

June 06, 2015

Presentation TVT 2015

PVR After TAVR Controversies: Clinical Relevance, Diagnostic Considerations, and Postdilation Strategies

Presenter: Susheel K. Kodali

June 05, 2015

Presentation TVT 2015

The Association of Paravalvular Regurgitation After TAVR and Subsequent Mortality: Comprehensive Review of the Literature and Observations From PARTNER and US CoreValve Trials

Presenter: Jeffrey J. Popma, John G. Webb, Susheel K. Kodali

June 05, 2015

Presentation TVT 2015

Updates From the US FDAApproved Sentinel TAVR Safety and Efficacy Study

Presenter: Susheel K. Kodali

June 05, 2015

Presentation TVT 2015

The Thubrikar TAVR System

Presenter: Susheel K. Kodali

June 05, 2015

Presentation ACC 2015

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

Presenter: Susheel K. Kodali

March 15, 2015

News Conference News ACC 2015

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Yael L. Maxwell

March 15, 2015

News Industry News

SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk Patients

March 15, 2015

News Daily News

Un Análisis del PARTNER Analiza los Predictores e Impacto Clínico de la Implantación de Marcapasos

January 28, 2015

News Daily News

PARTNER 分析揭示起搏器置入的预测因素和临床影响

January 28, 2015

Advertisement

Which Valve, Which Size, and Why, Part 2? Self Expanding

Which Valve, Which Size, and Why, Part 1? Balloon Expandable

Transfemoral TAVR: Current indications and results

已有或新发房颤均会使TAVR疗效变差

La FA, Preexistente o de Nueva Aparición, se asoció a Peores Resultados en la TAVR

A-fib, Whether Preexisting or New-Onset, Tied to Poor Outcomes in TAVR

An Interventionalists View: Flying Solo or With a Copilot?

A Surgeons View: Will I Be in the Room in the Future?

The Era of Tailored Care: Implementing Risk Stratification and Individualized Device Selection

New Indications Coming: The Role of the Heart Team in the Assessment of Intermediate- and Low-Risk Patients

Looking Back to Move Forward: Learning From Past Blunders to Strengthen the Heart Team

PVR After TAVR Controversies: Clinical Relevance, Diagnostic Considerations, and Postdilation Strategies

The Association of Paravalvular Regurgitation After TAVR and Subsequent Mortality: Comprehensive Review of the Literature and Observations From PARTNER and US CoreValve Trials

Updates From the US FDAApproved Sentinel TAVR Safety and Efficacy Study

The Thubrikar TAVR System

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk Patients

Un Análisis del PARTNER Analiza los Predictores e Impacto Clínico de la Implantación de Marcapasos

PARTNER 分析揭示起搏器置入的预测因素和临床影响

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content